EW Logo

Edwards Lifesciences Corporation (EW) 

NYSE
Market Cap
$41.6B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
271 of 774
Rank in Industry
37 of 99

Largest Insider Buys in Sector

EW Stock Price History Chart

EW Stock Performance

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, …

Insider Activity of Edwards Lifesciences Corporation

Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $49,753 and sold $41.55M worth of Edwards Lifesciences Corporation stock.

On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $80.68M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Zovighian Bernard J (CEO) — $49,753.

The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.

List of Insider Buy and Sell Transactions, Edwards Lifesciences Corporation

2024-11-13SaleCVP,Strategy/Corp Development
5,000
0.0008%
$65.57$327,843+3.20%
2024-11-05SaleGlobal President TAVR & Surg
25,000
0.0041%
$65.91$1.65M-0.10%
2024-10-15SaleCVP,Strategy/Corp Development
5,000
0.0009%
$69.51$347,534-1.97%
2024-09-11SaleCVP,Strategy/Corp Development
5,000
0.0008%
$66.77$333,826+2.04%
2024-08-20SaleCVP, TMTT
1,250
0.0002%
$69.95$87,438-2.15%
2024-08-14SaleCVP,Strategy/Corp Development
5,000
0.0008%
$66.08$330,4200.00%
2024-07-11SaleCVP, JAPAC
500
<0.0001%
$94.18$47,0900.00%
2024-07-10SaleCVP,Strategy/Corp Development
5,000
0.0008%
$93.29$466,4740.00%
2024-06-20SaleCVP, Chief Financial Officer
5,625
0.0009%
$87.51$492,258-23.58%
2024-06-20SaleCVP, JAPAC
535
<0.0001%
$90.00$48,150-23.58%
2024-06-12SaleCVP,Strategy/Corp Development
5,000
0.0008%
$87.54$437,697-22.38%
2024-05-30SaleCEO
8,617
0.0014%
$87.68$755,539-22.07%
2024-05-21SaleCVP, Chief Financial Officer
5,625
0.0009%
$90.45$508,803-24.05%
2024-05-10SaleCVP,Strategy/Corp Development
5,000
0.0008%
$87.81$439,038-20.52%
2024-05-07SaleCVP, JAPAC
857
0.0001%
$85.60$73,359-19.47%
2024-05-06PurchaseCEO
580.26
<0.0001%
$85.74$49,753-18.49%
2024-05-02Saledirector
29,350
0.0049%
$84.77$2.49M-18.46%
2024-05-01SaleCVP, EMEACLA and JAPAC
14,400
0.0024%
$84.21$1.21M-17.66%
2024-04-30SaleCVP, Chief Financial Officer
7,250
0.0012%
$85.80$622,062-18.05%
2024-04-09SaleCVP, JAPAC
857
0.0001%
$92.34$79,135-24.56%

Insider Historical Profitability

17.7%
Zovighian Bernard JCEO
68218
0.0116%
$70.5416
GALLAHUE KIERANdirector
67219
0.0114%
$70.5422+27.32%
Szyman Catherine M.CVP, Critical Care
34814
0.0059%
$70.54156+31.99%
VALERIANI NICHOLAS Jdirector
63811
0.0108%
$70.5411<0.0001%
PYOTT DAVID E Idirector
48429
0.0082%
$70.5416+10.01%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$5.06B8.7952.96M+1.15%+$57.43M0.09
BlackRock$5.01B8.752.42M+0.47%+$23.59M0.11
State Street$2.56B4.4426.78M-0.67%-$17.19M0.11
BNY Mellon$1.81B3.1518.97M+9.49%+$157.18M0.34
Brown Advisory$1.59B2.7616.64M-8.5%-$147.67M2.13
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.